Chromic gut suture reduces calcitonin-gene-related peptide and substance P levels in the spinal cord following chronic constriction injury in the rat.
The chronic constriction injury (CCI) is an animal model of an experimental peripheral neuropathy. In this model, a mononeuropathy is produced by loosely ligating the left sciatic nerve of the rat with chromic gut suture (Bennett and Xie 1988). Maves et al. (1993) have proposed that chemical constituents of chromic gut suture influence the behavioral changes of rats with the CCI. Considering their results, we became interested in evaluating whether the type of suture material used to produce the CCI also affected spinal levels of calcitonin-gene-related peptide immunoreactivity (CGRP-ir) and substance P immunoreactivity (SP-ir), peptides that are associated with small primary afferent neurons. Using methods of radioimmunoassay (RIA), we measured levels of CGRP-ir and SP-ir in the dorsal quadrants of approximately the lumbar 4-5 (L4-L5) spinal segments of rats with a CCI induced using polyglactin (Vicryl), plain gut, or chromic gut suture. We observed bilateral decreases in CGRP-ir and SP-ir 60 days after a CCI induced with chromic gut suture, but no changes in peptide levels after a CCI induced with either polyglactin or plain gut suture. These results suggest two possibilities: (1) chromic gut suture, when used to produce the CCI, has more than just a constrictive effect on the sciatic nerve, and/or (2) different suture materials produce changes in CGRP-ir and SP-ir with a differential time-course. Our experiments are unable to distinguish between these two possibilities.
Xu
Jiangyan
J
Department of Oral Science, 17-252 Moos Tower, University of Minnesota, Minneapolis, MN 55455-0329, USA Department of Psychology, University of Minnesota, Minneapolis, MN 55455-0329, USA Department of Cell Biology and Neuroanatomy, and Program in Neuroscience, Minneapolis, MN 55455-0329, USA.
Pollock
Carol H
CH
Kajander
Keith C
KC
D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism*; D017608:Chromium Compounds / Q000009:adverse effects*; D002908:Chronic Disease; D003251:Constriction, Pathologic / Q000378:metabolism / Q000473:pathology; D008297:Male; D009419:Nerve Tissue Proteins / Q000378:metabolism; D010146:Pain / Q000378:metabolism* / Q000473:pathology / Q000523:psychology; D059348:Peripheral Nerve Injuries; D010525:Peripheral Nerves / Q000378:metabolism / Q000473:pathology; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000293:injuries / Q000473:pathology; D013116:Spinal Cord / Q000378:metabolism*; D013373:Substance P / Q000378:metabolism*; D013537:Sutures
D017608:Chromium Compounds; D009419:Nerve Tissue Proteins; D013373:Substance P; D015740:Calcitonin Gene-Related Peptide